Business · 04/03/2024Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM
Summary
The US Food and Drug Administration has published a notice determining the regulatory review period for the SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM, following a patent extension application submitted to the US Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →